Schedule 13G ownership disclosure

XTL BIOPHARMACEUTICALS LTD

Security class unavailable · CUSIP: 98386D307

Event date: 2017-12-31

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
66,666
Percent of class
1.4600%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001535610-18-000018
Form type
SC 13G
Filer
SABBY MANAGEMENT, LLC
CIK
CIK 1535610
Filed
Jan 05, 2018
Reporting period
Dec 31, 2017
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub